scholarly journals Prolonged Cefoxitin Infusion Using Mobile Elastomeric Infusors In Outpatients With Bone And Joint Infection

2018 ◽  
Vol 3 (4) ◽  
pp. 182-186 ◽  
Author(s):  
Zoé Cavalli ◽  
Agathe Becker ◽  
Alexie Bosch ◽  
Anne Conrad ◽  
Claire Triffault-Filit ◽  
...  

Abstract. We reviewed all outpatients with bone and joint infection treated with cefoxitin in continuous intravenous infusion using mobile elastomeric infusors in our regional reference center between 2014 and 2017. The stability of cefoxitin provides an interesting and well-tolerated alternative for continuous infusion in outpatients with polymicrobial bone and joint infection.

1954 ◽  
Vol 32 (4) ◽  
pp. 428-433 ◽  
Author(s):  
B. Kinash ◽  
R. E. Haist

A method is described for the continuous intravenous infusion of fluids in the unanesthetized rat. When rats were infused continuously with glucose solutions for 6–14 days the total amount of islet tissue was greatly increased, as compared to that of saline-infused controls. This increase was evident also when considered in relation to pancreas weight or body weight.


1983 ◽  
Vol 17 (3) ◽  
pp. 196-197 ◽  
Author(s):  
J. H. Cookson ◽  
F. J. Mills

39 experiments were carried out in baboons using continuous intravenous infusion of alphaxalone-alphadolone as an anaesthetic for periods of up to 6 h. This steroid anaesthetic was found to be safe and reliable, with smooth, rapid induction, uneventful recovery, and no evidence of cumulative effect.


1976 ◽  
Vol 10 (1) ◽  
pp. 69-72 ◽  
Author(s):  
H. Saarni ◽  
J. Viikari

A lateral tail vein of the rat is used as the route for continuous infusion. The animal is kept under neuroleptic tranquilisation during the infusion.


1988 ◽  
Vol 41 (4) ◽  
pp. 453 ◽  
Author(s):  
D Leenanuruksa ◽  
P Niumsup ◽  
GH McDowell

Effects of insulin on exchanges of glucose across skeletal muscle and mammary tissue were measured in short-term studies in lactating ewes. Insulin secretion was suppressed by a primed/continuous infusion of somatostatin, then insulin was administered by continuous intravenous infusion of doses that were increased, in a step-wise manner, from 0 to 2 U h -I. Plasma glucose was maintained essentially constant by frequent monitoring and intravenous administration of exogenous glucose.


1992 ◽  
Vol 26 (10) ◽  
pp. 1221-1226 ◽  
Author(s):  
Roy A. Pleasants ◽  
Leigh M. Vaughan ◽  
Dennis M. Williams ◽  
Janet L. Fox

OBJECTIVE: Aminophylline and ceftazidime are sometimes used concurrently in patients with respiratory disorders. Parenteral aminophylline usually is administered as a constant infusion, and ceftazidime is given intermittently or less commonly as a constant infusion. We evaluated the stability and compatibility of the two drugs when aminophylline is given as a constant intravenous infusion and ceftazidime is administered simultaneously either through a y-site (piggyback method) or as a continuous infusion (constant infusion method). DESIGN: The chemical stability of intravenous aminophylline and ceftazidime in dextrose 5% and NaCl 0.9% for both methods was studied. Three different formulations of ceftazidime from the same manufacturer were studied (minibag using reconstituted ceftazidime, premixed minibag, and ceftazidime arginine). For the piggyback and constant infusion methods, samples were collected at 0,1, and 2 hours; and 0,6, and 24 hours, respectively. All experiments were conducted in triplicate. Samples were analyzed in duplicate by a stability-indicating HPLC assay method. OUTCOME MEASURE: Ceftazidime and aminophylline were considered stable if concentrations remained above 90 percent of the original concentrations over the time periods studied. RESULTS: Ceftazidime was determined to be compatible with aminophylline in the piggyback method. In contrast, when aminophylline and ceftazidime were admixed in the same intravenous container (constant infusion method), the two drugs were not stable. CONCLUSIONS: These data indicate that aminophylline and ceftazidime admixtures are incompatible when prepared in the same intravenous container, which may occur if both are given as a constant infusion. The two drugs are compatible when the ceftazidime is piggybacked into a primary intravenous set in which aminophylline is administered as a constant infusion.


1985 ◽  
Vol 38 (4) ◽  
pp. 393 ◽  
Author(s):  
TN Barry ◽  
GJ Faichney ◽  
Carolyn Redekopp

The effect of a 5-day continuous intravenous infusion of somatostatin (4�6 ng min- I kg-I) was studied, using anoestrous ewes given 791 g dry matter per day of a 60: 40 lucerne hay: oat grain pelleted diet from a continuously moving belt. 5ICr-EDTA, I03Ru-phenanthroline and lignin were used as markers to determine digesta mean retention times (MRT) by a continuous infusion-total sampling procedure.


1996 ◽  
Vol 30 (1) ◽  
pp. 75-78 ◽  
Author(s):  
D. J. van Kleef

The swivel system described has been used by ILOB-TNO for prolonged periods of continuous infusion. It allows for less restricted movement of animals. The swivel prevents the infusion tube from twisting. The swivel system is simple, safe to operate and cost-effective. Animals have greater movement, can stretch and turn around. The physical discomfort and psychological stress of restricted movement are greatly reduced. The potentially complicating/confusing effects on the measurements taken during an experiment are reduced.


2018 ◽  
Vol 103 (2) ◽  
pp. e1.11-e1
Author(s):  
Whitticase Louise

AimThe aim of this audit was to examine whether the continuous intravenous infusion prescription chart is an accurate reflection of the infusions the baby is actually receiving. The neonatal continuous infusion prescription charts were redesigned six months ago to reduce the prescribing burden of rewriting all continuous infusions on the Neonatal Intensive Care Unit (NICU) on a daily basis. On the new charts the prescription remains valid until it is crossed off or for a maximum period of 7 days. The impression of the pharmacist however is that prescribers are not always crossing off the prescription when they stop an infusion.MethodData collection commenced in June 2017 by the Lead Neonatal Pharmacist. All babies on NICU on a Monday for a period of 4 weeks were included. The continuous infusion prescription chart was compared to the continuous infusions actually being administered to each baby and the corresponding numbers recorded. Any prescriptions identified that were no longer being administered but had not been crossed off were marked as ‘inactive’ by the pharmacist and the nurse/prescriber made aware. The results were fed back the same day to the nurses/prescribers on shift by the pharmacist and cascaded to the Lead Neonatal Consultant for Medication Safety and Chair of Drug and Therapeutics Committee for dissemination to the wider neonatal team via email.A poster was designed and displayed on the ward to highlight the results.ResultsWeek 1–107 infusions prescribed; 60 being administered (47(44%) inactive prescriptions)Week 2–27 infusions prescribed; 21 being administered (6 (22%) inactive prescriptions)Week 3–26 infusions prescribed, 24 being administered (2 (8%) inactive prescriptions)Week 4–23 infusions prescribed, 20 being administered (3 (13%) inactive prescriptions)ConclusionThe continuous intravenous infusion prescription chart was not an accurate reflection of the medications a baby was actually receiving at the start of the audit; 44% of infusions prescribed were no longer being administered. The number of prescriptions crossed off when the decision was taken to stop the infusion improved throughout the 4 week period. By week 3 the majority of continuous infusion prescription charts matched the medications the baby was actually receiving. Both the infusions identified as inactive in week 3 and 2 out of the 3 infusions in week 4 were inotropes that had been slowly weaned to stop following the decision to stop on the ward round. These prescriptions were unable to be crossed off at the time the decision was made to stop the infusion, as the intention was to wean to stop; however the nurses informed the pharmacist conducting the audit that the prescribers were aware the infusions had now stopped and were due to come back and cross off the prescriptions.This audit demonstrates that a regular pharmacist presence highlighting issues with prescribing practice can drive change quite quickly and promote compliance with good prescribing procedures. Training has been incorporated in to the doctor induction programme and neonatal nurse training. The plan is to repeat the audit monthly to ensure compliance is maintained.


Blood ◽  
1965 ◽  
Vol 26 (3) ◽  
pp. 281-295 ◽  
Author(s):  
STEPHEN H. ROBINSON ◽  
GEORGE BRECHER ◽  
IRA S. LOURIE ◽  
JAMES E. HALEY

Abstract Leukocyte labeling was studied in rats during and after continuous intravenous infusion of H3-thymidine. The radioisotope was administered for varying periods up to 271 days. The results permit the following conclusions: 1. The median survival of small lymphocytes is about 1 month. Five to 8 per cent of small lymphocytes have a life span of more than 9 months. 2. Following the administration of H3-thymidine, reutilization of the tracer markedly delays the fall-off of labeled cells in the peripheral blood. Reutilization probably involves H3-thymidine released from labeled DNA during cell death, since suppression occurs with massive infusion of non-labeled thymidine. 3. Unlike granulocytes and large lymphocytes, small lymphocytes label nonuniformly, and appear to be comprised of at least two populations with different intensities of labeling and different turnover rates. The more heavily labeled cells have the faster turnover. 4. The complexity of the labeling process indicated by the present observations must be considered in the interpretation of H3-thymidine data. However, the survival of unlabeled cells during continuous H3-thymidine infusion remains a valid means of measuring the life spans of circulating blood cells.


Sign in / Sign up

Export Citation Format

Share Document